New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression Of Joint Damage In Rheumatoid Arthritis Patients

One-year data from a two-year Phase III study demonstrated that ACTEMRA(R) (tocilizumab) significantly inhibited the progression of structural joint damage in patients with rheumatoid arthritis (RA). Late-breaking results from the LITHE study will be featured as an oral presentation during the American College of Rheumatology (ACR) Annual Scientific Meeting (October 24-28) in San Francisco.